

Capstone Therapeutics Corp.  
Form DEFA14A  
June 08, 2011  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

SCHEDULE 14A  
(RULE 14A – 101)  
INFORMATION REQUIRED IN PROXY STATEMENT

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES  
EXCHANGE ACT OF 1934 (AMENDMENT NO. \_\_)

Filed by the Registrant  [x]  
Filed by a party other than the Registrant  [ ]

Check the appropriate box:

- [ ] Preliminary proxy statement.  
 [ ] Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)).  
 [ ] Definitive proxy statement.  
 [X] Definitive additional materials.  
 [ ] Soliciting material pursuant to §240.14a-12.

CAPSTONE THERAPEUTICS CORP.  
(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of filing fee (check the appropriate box):

- [X] No fee required.  
 [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- 1) Title of each class of securities to which transaction applies: \_\_\_\_\_
- 2) Aggregate number of securities to which transaction applies: \_\_\_\_\_
- 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):  
\_\_\_\_\_
- 4) Proposed maximum aggregate value of transaction: \_\_\_\_\_
- 5) Total fee paid: \_\_\_\_\_

- [ ] Fee paid previously with preliminary materials.  
 [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Edgar Filing: Capstone Therapeutics Corp. - Form DEFA14A

1) Amount Previously Paid: \_\_\_\_\_

2) Form, Schedule or Registration Statement No.: \_\_\_\_\_

3) Filing Party: \_\_\_\_\_

4) Date Filed: \_\_\_\_\_



1275 West Washington Street - Suite 101  
Tempe, AZ 85281  
(602) 286-5520  
www.capstonethx.com  
Nasdaq: CAPS

FOR FURTHER INFORMATION:

Karen Struck, Investor Relations  
(602) 286-5250  
kstruck@capstonethx.com

Lauren Glaser – The Trout Group  
(415) 392-3310  
lglaser@troutgroup.com

Capstone Therapeutics announces adjournment of its  
annual meeting of stockholders and intention to reconvene the meeting on June 28, 2011

Tempe, AZ – June 8, 2011 Capstone Therapeutics (Nasdaq: CAPS; the “Company”) announced that at its Annual Meeting held on Monday June 6, 2011, there were insufficient shares represented by person or by proxy at the meeting to establish a quorum for the election of directors. Accordingly, the meeting was adjourned and scheduled to reconvene on June 28, 2011 at 10:00 AM PDT at the Company’s offices located at 1275 W. Washington Street, Suite 101, Tempe, Arizona.

Brokers are no longer allowed to vote without instructions on the election of directors, making it very important for stockholders to vote to ensure sufficient votes are present to achieve a quorum. Without a quorum, the directors cannot be elected at the reconvened meeting. Stockholders are requested to either return their proxy cards in the envelope provided with the previously delivered proxy materials or vote on [www.proxyvote.com](http://www.proxyvote.com). Stockholders may contact their broker to obtain their voter identification number if they no longer can locate their proxy card.

Copies of the Company’s proxy materials are available at [www.capstonethx.com](http://www.capstonethx.com) .

Capstone’s corporate headquarters are in Tempe, Arizona. For more information, please visit the Company's website: [www.capstonethx.com](http://www.capstonethx.com).

###

Editor’s Note: This press release is also available under the Investors section of the Company’s website at [www.capstonethx.com](http://www.capstonethx.com).